ZA201403735B - Pharmaceutical formulations comprising atorvastatin and glimepiride - Google Patents
Pharmaceutical formulations comprising atorvastatin and glimepirideInfo
- Publication number
- ZA201403735B ZA201403735B ZA2014/03735A ZA201403735A ZA201403735B ZA 201403735 B ZA201403735 B ZA 201403735B ZA 2014/03735 A ZA2014/03735 A ZA 2014/03735A ZA 201403735 A ZA201403735 A ZA 201403735A ZA 201403735 B ZA201403735 B ZA 201403735B
- Authority
- ZA
- South Africa
- Prior art keywords
- glimepiride
- atorvastatin
- pharmaceutical formulations
- formulations
- pharmaceutical
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 1
- 229960005370 atorvastatin Drugs 0.000 title 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 title 1
- 229960004346 glimepiride Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3920CH2011 | 2011-11-15 | ||
| US201261582566P | 2012-01-03 | 2012-01-03 | |
| PCT/IB2012/002860 WO2013072770A2 (en) | 2011-11-15 | 2012-11-14 | Pharmaceutical formulations comprising atorvastatin and glimepiride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201403735B true ZA201403735B (en) | 2015-12-23 |
Family
ID=48430284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/03735A ZA201403735B (en) | 2011-11-15 | 2014-05-22 | Pharmaceutical formulations comprising atorvastatin and glimepiride |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2779999A2 (en) |
| IN (1) | IN2014CN04119A (en) |
| RU (1) | RU2014124118A (en) |
| WO (1) | WO2013072770A2 (en) |
| ZA (1) | ZA201403735B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4153145A4 (en) * | 2020-05-18 | 2024-05-29 | Univ Texas | Granules for 3d printing technology |
| CN112618499B (en) * | 2020-12-24 | 2022-09-30 | 石药集团欧意药业有限公司 | Glimepiride dispersible tablet composition and preparation method thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2951135A1 (en) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | SULFONYL UREAS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE |
| DE3320582A1 (en) | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | METHODS OF PREPARATION WITH GLIQUIDONE AND METHOD FOR THE PRODUCTION THEREOF |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (en) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
| ES2133158T3 (en) | 1993-01-19 | 1999-09-01 | Warner Lambert Co | FORMULATION CI-981 ORAL, STABLE AND PREPARATION PROCESS OF THE SAME. |
| CZ294108B6 (en) | 1995-07-17 | 2004-10-13 | Warner@Lambertácompany | Crystalline form I of atorvastatin hydrate, i.e. [R-(R*,R*)]-2-(4-fluorophenyl)- beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt |
| SI20109A (en) | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stable pharmaceutical formulation |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| US6558659B2 (en) | 2000-04-10 | 2003-05-06 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| WO2001093859A1 (en) | 2000-06-09 | 2001-12-13 | Lek Pharmaceuticals D.D. | Stable pharmaceutical product and formulation |
| EP1292293B1 (en) | 2000-06-09 | 2004-02-25 | Lek Pharmaceutical and Chemical Co. D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| PE20020323A1 (en) | 2000-08-22 | 2002-06-13 | Novartis Ag | PHARMACEUTICAL COMPOSITION INCLUDING AN INSULIN SECRETION ENHANCER AND HMG-Co-A-REDUCTASE INHIBITORS OR ANGIOTENSIN CONVERTER ENZYME (ACE) INHIBITORS |
| US7074818B2 (en) | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
| OA12777A (en) | 2002-02-14 | 2006-07-06 | Ranbaxy Lab Ltd | Formulations of atorvastatin stabilized with alkali metal additions. |
| US20030171407A1 (en) | 2002-03-07 | 2003-09-11 | Upsher-Smith Laboratories, Inc. | Composition for reducing blood glucose and cholesterol |
| CA2385529A1 (en) | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Stable dosage forms comprising atorvastatin calcium |
| SI21302A (en) | 2002-10-11 | 2004-04-30 | LEK farmacevtska dru�ba d.d. | Stabilized pharmaceutical product with amorphous active ingredient |
| US20040147564A1 (en) | 2003-01-29 | 2004-07-29 | Rao Vinay U. | Combinations of glimepiride and the thiazolidinedione for treatment of diabetes |
| SI21400A (en) | 2003-02-12 | 2004-08-31 | LEK farmacevtska družba d.d. | Stable pharmaceutical form with hmg-coa reductase inhibitor |
| CA2465565A1 (en) | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| WO2006006021A2 (en) | 2004-06-28 | 2006-01-19 | Glenmark Pharmaceuticals Limited | Stabilized pharmaceutical compositions of preferably a statin |
| WO2006039441A2 (en) | 2004-09-30 | 2006-04-13 | Dr. Reddy's Laboratories Ltd. | Amorphous atorvastatin calcium |
| US8623405B2 (en) | 2005-01-28 | 2014-01-07 | Takeda Pharmaceutical Company Limited | Finely divided composition containing poorly water soluble substance |
| EP1928421A2 (en) | 2005-06-10 | 2008-06-11 | Combino Pharm, S.L. | Formulations containing glimepiride and/or its salts |
| CN101103990A (en) * | 2006-07-14 | 2008-01-16 | 北京华安佛医药研究中心有限公司 | Composition containing sulfonylureas sugar-reducing drug and statins lipid-lowering drug |
| WO2008039894A2 (en) | 2006-09-27 | 2008-04-03 | Dr. Reddy's Labortories, Ltd. | Atorvastatin pharmaceutical compositions |
| WO2009140341A2 (en) * | 2008-05-13 | 2009-11-19 | Dr. Reddy's Laboratories Ltd. | Atorvastatin compositions |
-
2012
- 2012-11-14 EP EP12826534.5A patent/EP2779999A2/en not_active Withdrawn
- 2012-11-14 IN IN4119CHN2014 patent/IN2014CN04119A/en unknown
- 2012-11-14 WO PCT/IB2012/002860 patent/WO2013072770A2/en active Application Filing
- 2012-11-14 RU RU2014124118/15A patent/RU2014124118A/en not_active Application Discontinuation
-
2014
- 2014-05-22 ZA ZA2014/03735A patent/ZA201403735B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013072770A2 (en) | 2013-05-23 |
| EP2779999A2 (en) | 2014-09-24 |
| WO2013072770A3 (en) | 2013-10-24 |
| IN2014CN04119A (en) | 2015-07-10 |
| RU2014124118A (en) | 2015-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253870B (en) | Certain amino-pyrimidines and pharmaceutical compositions comprising them | |
| HK1215948A1 (en) | Amide compound and pharmaceutical application therefor | |
| HK1259250A1 (en) | Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives | |
| HRP20181896T1 (en) | Pharmaceutical formulations | |
| EP2718283A4 (en) | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof | |
| GB2486567B (en) | Pharmaceutical formulation | |
| HK1198137A1 (en) | Disinfecting formulations and uses thereof | |
| EP2775831A4 (en) | Pharmaceutical compositions and uses thereof | |
| EP2597084A4 (en) | N-hydroxyformamide derivative and pharmaceutical containing same | |
| HK1208676A1 (en) | Novel benzazepine derivative and pharmaceutical use thereof | |
| HRP20141173T1 (en) | Pharmaceutical comprising myramistin | |
| ZA201403735B (en) | Pharmaceutical formulations comprising atorvastatin and glimepiride | |
| HK1209339A1 (en) | Pharmaceutical formulations | |
| IL227905A0 (en) | Toroidal pharmaceutical formulations | |
| EP2668961A4 (en) | Combined pharmaceutical preparation | |
| GB201012046D0 (en) | Pharmaceutical formulations | |
| GB201012047D0 (en) | Pharmaceutical formulations | |
| GB201112578D0 (en) | Pharmaceutical preparation and use | |
| GB201111577D0 (en) | Pharmaceutical formulations | |
| PL390620A1 (en) | Pharmaceutical preparation | |
| GB201211403D0 (en) | Pharmaceutical formulations | |
| GB201211406D0 (en) | Pharmaceutical formulations | |
| IL227250A (en) | Analgesic compounds and pharmaceutical formuations comprising them | |
| ZA201105275B (en) | Pharmaceutical formulation containing atorvastatin and method for the preparation thereof | |
| ZA201301851B (en) | Pharmaceutical combinations |